230 related articles for article (PubMed ID: 31610404)
1. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders.
Novi G; Bovis F; Capobianco M; Frau J; Mataluni G; Curti E; Zuliani L; Cavalla P; Brambilla L; Annovazzi P; Repice AM; Lanzillo R; Esposito S; Benedetti L; Maietta I; Sica F; Buttari F; Malucchi S; Fenu G; Landi D; Bosa C; Realmuto S; Malentacchi M; Granella F; Signori A; Bonavita S; Uccelli A; Sormani MP;
Mult Scler Relat Disord; 2019 Nov; 36():101430. PubMed ID: 31610404
[TBL] [Abstract][Full Text] [Related]
2. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
[TBL] [Abstract][Full Text] [Related]
3. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
Zéphir H; Bernard-Valnet R; Lebrun C; Outteryck O; Audoin B; Bourre B; Pittion S; Wiertlewski S; Ouallet JC; Neau JP; Ciron J; Clavelou P; Marignier R; Brassat D
J Neurol; 2015 Oct; 262(10):2329-35. PubMed ID: 26194198
[TBL] [Abstract][Full Text] [Related]
4. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
Ongphichetmetha T; Jitprapaikulsan J; Siritho S; Rattanathamsakul N; Detweeratham T; Prayoonwiwat N
Sci Rep; 2024 Feb; 14(1):3503. PubMed ID: 38347079
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
Annovazzi P; Capobianco M; Moiola L; Patti F; Frau J; Uccelli A; Centonze D; Perini P; Tortorella C; Prosperini L; Lus G; Fuiani A; Falcini M; Martinelli V; Comi G; Ghezzi A
J Neurol; 2016 Sep; 263(9):1727-35. PubMed ID: 27286847
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
[TBL] [Abstract][Full Text] [Related]
8. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
Cui L; Jiao J; Zhang Y; Wang R; Peng D; Jiao Y; Zhang W
Mult Scler Relat Disord; 2024 Jun; 86():105600. PubMed ID: 38579568
[TBL] [Abstract][Full Text] [Related]
9. Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review.
Abbadessa G; Miele G; Maida E; Minervini G; Lavorgna L; Bonavita S
Mult Scler Relat Disord; 2022 Jul; 63():103926. PubMed ID: 35661568
[TBL] [Abstract][Full Text] [Related]
10. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
11. Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México.
Casallas-Vanegas A; Gomez-Figueroa E; de Saráchaga AJ; Zabala-Angeles I; García-Estrada C; Salado-Burbano JC; DiazGranados-Palacio MC; Corona-Vázquez T; de Jesús Flores-Rivera J; Rivas-Alonso V
J Neurol Sci; 2020 Dec; 419():117204. PubMed ID: 33161302
[TBL] [Abstract][Full Text] [Related]
12. Tailoring B cell depletion therapy in MS according to memory B cell monitoring.
Novi G; Bovis F; Fabbri S; Tazza F; Gazzola P; Maietta I; Currò D; Bruschi N; Roccatagliata L; Boffa G; Lapucci C; Pesce G; Cellerino M; Solaro C; Laroni A; Capello E; Mancardi G; Sormani M; Inglese M; Uccelli A
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32753406
[TBL] [Abstract][Full Text] [Related]
13. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
[TBL] [Abstract][Full Text] [Related]
14. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Nasir M; Hone L; Tallantyre E; Kelly P; Leite MI; Robertson N; Bestwick J; Huda S; Palace J; Dobson R
Mult Scler Relat Disord; 2024 May; 85():105528. PubMed ID: 38479046
[TBL] [Abstract][Full Text] [Related]
15. Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study.
Bruschi N; Malentacchi M; Malucchi S; Sperli F; Martire S; Sala A; Valentino P; Bertolotto A; Pautasso M; Capobianco MA
Neurol Ther; 2023 Aug; 12(4):1375-1383. PubMed ID: 37166677
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
17. Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder.
Shi B; Zhao M; Qiao L; Huang F; Zhou S; Wei Y; Wang J; Wang N
Mult Scler Relat Disord; 2021 Sep; 54():103143. PubMed ID: 34273608
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic strategies in NMOSD and MOGAD patients: A multicenter cohort study in Latin America.
Rojas JI; López PA; Criniti J; Pettinicchi JP; Caride A; Correa Díaz EP; Toral Granda AM; Ortiz Yepez MA; Gualotuña Pachacama WA; Andrade JSP; Daccach Marques V; Bribiesca Contreras E; Gómez Figueroa E; Flores Rivera J; Galleguillos L; Navas C; Soares Neto HR; Gracia F; Cristiano E; Patrucco L; Becker J; Hamuy F; Alonso R; Man F; Tkachuk V; Nadur D; Lana-Peixoto M; Castillo IS; Carnero Contentti E
Mult Scler Relat Disord; 2023 Mar; 71():104508. PubMed ID: 36738691
[TBL] [Abstract][Full Text] [Related]
19. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.
Shaygannejad V; Fayyazi E; Badihian S; Mirmosayyeb O; Manouchehri N; Ashtari F; Asgari N
J Neurol; 2019 Mar; 266(3):642-650. PubMed ID: 30635724
[TBL] [Abstract][Full Text] [Related]
20. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
